Rolando Pérez
YOU?
Author Swipe
View article: Insights into the forests of Darién, Panama, from the new 10 ha <i>Bacurú Drõa</i> plot established through participatory methods within an Emberá territory
Insights into the forests of Darién, Panama, from the new 10 ha <i>Bacurú Drõa</i> plot established through participatory methods within an Emberá territory Open
Networks of forest plots are key for documenting how forests are responding to climate change; however, very few plots are in inaccessible locations, and almost no research is carried out in Indigenous territories. We present the first dat…
View article: Mejoras al sistema de mantenimiento de los equipos radioelectrónicos de las empresas en el territorio norte holguinero
Mejoras al sistema de mantenimiento de los equipos radioelectrónicos de las empresas en el territorio norte holguinero Open
El presente trabajo se enfocó en el análisis de la gestión del mantenimiento de los equipos radio electrónico de las empresas en el territorio norte holguinero (ETNH), se establecieron cambios que contribuyeron a un mejor funcionamiento y …
View article: Lifespan of tropical trees from seed to 1-cm diameter
Lifespan of tropical trees from seed to 1-cm diameter Open
View article: Procedimientos guiados por ultrasonido en el punto de atención (POCUS): desde la óptica pediátrica
Procedimientos guiados por ultrasonido en el punto de atención (POCUS): desde la óptica pediátrica Open
La utilización del modelo de ecografía en el punto de atención a veces mencionada como POCUS por sus siglas en inglés (Point of Care Ultrasound) para guiar los procedimientos invasivos en pediatría, ha generado un cambio de paradigma en la…
View article: Putting seedlings on the map: Trade‐offs in demographic rates between ontogenetic size classes in five tropical forests
Putting seedlings on the map: Trade‐offs in demographic rates between ontogenetic size classes in five tropical forests Open
All species must partition resources among the processes that underly growth, survival, and reproduction. The resulting demographic trade‐offs constrain the range of viable life‐history strategies and are hypothesized to promote local coex…
View article: The Barro Colorado Island Liana Oligarchy: Dominance, Distribution, and Traits of the 10 Most Common Liana Species
The Barro Colorado Island Liana Oligarchy: Dominance, Distribution, and Traits of the 10 Most Common Liana Species Open
The 10 most dominant liana species of the Barro Colorado Island (BCI) 50-ha plot, which we refer to as the liana oligarchy, included 46.5% of the total rooted liana stems and 37% of the total rooted liana basal area in 2017. The oligarchs …
View article: Supplementary Table 2 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Supplementary Table 2 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients Open
PDF file - 66KB, Summary of adverse events.
View article: Supplementary Table 1 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Supplementary Table 1 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients Open
PDF file - 47KB, Adverse event severity.
View article: Supplementary Figure 2 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Supplementary Figure 2 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients Open
PDF file - 144KB, Overall survival HRs (racotumomab over placebo) in subgroups according to baseline characteristics.
View article: Supplementary Figure 1 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Supplementary Figure 1 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients Open
PDF file - 284KB, CONSORT study diagram.
View article: Supplementary Table 3 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Supplementary Table 3 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients Open
PDF file - 132KB, Number of doses received, maximal titer and isotype analysis against Racotumomab-mAb and NeuGcGM3, percentages of binding and cytotoxicity against L1210 cells, and survival times in vaccinated NSCLC patients.
View article: Data from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Data from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients Open
Purpose: Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 tumor-associated ganglioside. This clinical trial was conducted to provide a preliminary estimate of efficacy and safety of racotumomab as switch maintenan…
View article: Supplementary Table 5 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Supplementary Table 5 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients Open
PDF file - 137KB, Association of functional capacity of elicited anti-NeuGcGM3 antibodies with patient's survival.
View article: Supplementary Figure 2 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Supplementary Figure 2 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients Open
PDF file - 144KB, Overall survival HRs (racotumomab over placebo) in subgroups according to baseline characteristics.
View article: Supplementary Figure Legends from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Supplementary Figure Legends from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients Open
PDF file - 61KB
View article: Supplementary Table 4 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Supplementary Table 4 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients Open
PDF file - 2804KB, Association of antibody response with patient's survival.
View article: Supplementary Table 5 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Supplementary Table 5 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients Open
PDF file - 137KB, Association of functional capacity of elicited anti-NeuGcGM3 antibodies with patient's survival.
View article: Data from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Data from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients Open
Purpose: Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 tumor-associated ganglioside. This clinical trial was conducted to provide a preliminary estimate of efficacy and safety of racotumomab as switch maintenan…
View article: Supplementary Table 1 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Supplementary Table 1 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients Open
PDF file - 47KB, Adverse event severity.
View article: Supplementary Figure 1 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Supplementary Figure 1 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients Open
PDF file - 284KB, CONSORT study diagram.
View article: Supplementary Table 4 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Supplementary Table 4 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients Open
PDF file - 2804KB, Association of antibody response with patient's survival.
View article: Supplementary Figure Legends from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Supplementary Figure Legends from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients Open
PDF file - 61KB
View article: Supplementary Table 2 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Supplementary Table 2 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients Open
PDF file - 66KB, Summary of adverse events.
View article: Supplementary Table 3 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients
Supplementary Table 3 from A Randomized, Multicenter, Placebo-Controlled Clinical Trial of Racotumomab-Alum Vaccine as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients Open
PDF file - 132KB, Number of doses received, maximal titer and isotype analysis against Racotumomab-mAb and NeuGcGM3, percentages of binding and cytotoxicity against L1210 cells, and survival times in vaccinated NSCLC patients.
View article: Supplemental Figure Legend from Oncogenic Transformation Can Orchestrate Immune Evasion and Inflammation in Human Mesenchymal Stem Cells Independently of Extrinsic Immune-Selective Pressure
Supplemental Figure Legend from Oncogenic Transformation Can Orchestrate Immune Evasion and Inflammation in Human Mesenchymal Stem Cells Independently of Extrinsic Immune-Selective Pressure Open
Supplemental Figure Legend. Legend for Supplemental Figures S1-S12.
View article: Supplemental Figures S1-S12 from Oncogenic Transformation Can Orchestrate Immune Evasion and Inflammation in Human Mesenchymal Stem Cells Independently of Extrinsic Immune-Selective Pressure
Supplemental Figures S1-S12 from Oncogenic Transformation Can Orchestrate Immune Evasion and Inflammation in Human Mesenchymal Stem Cells Independently of Extrinsic Immune-Selective Pressure Open
Supplemental Figures S1-S12. qPCR validation of genes expression change identified by microarray analysis of HLA class I APM (S1); Increased inhibitory capacity of transformed hMSC is independent of cell lines proliferation rates (S2); Seq…
View article: Supplementary Table S1 from Oncogenic Transformation Can Orchestrate Immune Evasion and Inflammation in Human Mesenchymal Stem Cells Independently of Extrinsic Immune-Selective Pressure
Supplementary Table S1 from Oncogenic Transformation Can Orchestrate Immune Evasion and Inflammation in Human Mesenchymal Stem Cells Independently of Extrinsic Immune-Selective Pressure Open
Supplementary Table S1. Probe Set IDs for microarray's analysis.
View article: Data from Oncogenic Transformation Can Orchestrate Immune Evasion and Inflammation in Human Mesenchymal Stem Cells Independently of Extrinsic Immune-Selective Pressure
Data from Oncogenic Transformation Can Orchestrate Immune Evasion and Inflammation in Human Mesenchymal Stem Cells Independently of Extrinsic Immune-Selective Pressure Open
Immune escape is a hallmark of cancer, but whether it relies upon extrinsic immune-selective pressure or is inherently orchestrated by oncogenic pathways is unresolved. To address this question, we took advantage of an in vitro mode…
View article: Supplemental Methods and References from Oncogenic Transformation Can Orchestrate Immune Evasion and Inflammation in Human Mesenchymal Stem Cells Independently of Extrinsic Immune-Selective Pressure
Supplemental Methods and References from Oncogenic Transformation Can Orchestrate Immune Evasion and Inflammation in Human Mesenchymal Stem Cells Independently of Extrinsic Immune-Selective Pressure Open
Supplemental Methods and References. Description of additional methods and procedures used in the study. Also includes Supplemental References.
View article: Supplemental Methods and References from Oncogenic Transformation Can Orchestrate Immune Evasion and Inflammation in Human Mesenchymal Stem Cells Independently of Extrinsic Immune-Selective Pressure
Supplemental Methods and References from Oncogenic Transformation Can Orchestrate Immune Evasion and Inflammation in Human Mesenchymal Stem Cells Independently of Extrinsic Immune-Selective Pressure Open
Supplemental Methods and References. Description of additional methods and procedures used in the study. Also includes Supplemental References.